All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Mohamad Mohty, Saint-Antoine Hospital and Sorbonne University, Paris, FR, discusses practice-changing abstracts in multiple myeloma presented at ASH 2019.
Prof. Mohty discusses important trials in patients with relapsed/refractory multiple myeloma such as the CAR T trials CARTITUDE-1 and LEGEND-2, studies involving bispecific antibodies such as CC-93269, and new monoclonal antibodies such as TAK-079. Whilst the bispecific antibodies may challenge the role of CAR T in myeloma, Prof. Mohty notes that we will likely need to use all these tools, in different patient populations. Next, Prof. Mohty discusses key trials in smoldering myeloma, especially in high-risk patients, such as GEM-CESAR, and concludes by talking about advances in frontline therapy presented at ASH such as the ALCYONE trial.
Practice-changing abstracts in multiple myeloma presented at ASH 2019
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?